Psoriatic Arthritis Resource Center

Psoriatic arthritis (PsA) is distinguished from other forms of inflammatory arthritis by unique pathophysiology and manifestations. Important developments for rheumatologists and rheumatology professionals to note include the release of a PsA treatment guideline in early 2019, the development of patient outcome measures and studies that have demonstrated that tight control of disease activity leads to improvements in these outcome measures for patients. In this resource center, you’ll find our summary of the guideline, as well as a collection of important research reviews, case reports and clinical articles on advances in the diagnosis and management of PsA.

FEATURED ARTICLE: Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

First Biosimilar to Adalimumab Enters the U.S. Market After Years of Legal Battles

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.... [Read More]

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel… [Read More]

Challenges in Psoriatic Arthritis

PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but… [Read More]

Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my… [Read More]

FDA Approves Ustekinumab for Children with PsA

After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.... [Read More]

Psoriatic Arthritis & the Obese Patient

The National Psoriasis Foundation estimates that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden of cardiometabolic… [Read More]

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.... [Read More]

Phase 2 Study Shows Promising Results for Deucravacitinib in PsA

Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.... [Read More]

Spine School: Axial Manifestations of Psoriatic Arthritis

This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.... [Read More]

Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA

HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.... [Read More]